Xoma/Cooper Development
Executive Summary
Firms will not pursue a previously announced plan to collaborate on joint development and marketing of immunotoxins for use in treatment of bone marrow transplant rejection. Xoma said it intends to expand its bone marrow program to additional applications and Cooper has decided to focus on respiratory care. (NEW LINE)
Firms will not pursue a previously announced plan to collaborate on
joint development and marketing of immunotoxins for use in
treatment of bone marrow transplant rejection. Xoma said it intends
to expand its bone marrow program to additional applications and
Cooper has decided to focus on respiratory care. (NEW LINE) |